Hansa Biopharma: Continuing progress with gene therapy partners - Redeye
Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of GNT-0003 in the ultra-rare indication of Crigler-Najjar syndrome.
ANNONS
Hansa’s partner Genethon initiates a phase 2 study based on Imlifidase as a pre-treatment ahead of GNT-0003 in the ultra-rare indication of Crigler-Najjar syndrome.